Entrada Therapeutics (TRDA) Net Equity Issued and Repurchased (2021 - 2024)
Entrada Therapeutics' (TRDA) quarterly Net Equity Issued and Repurchased came in at -$392000.0 in Q3 2024, down 100.39% quarter-over-quarter from $100.0 million in Q2 2024.
Entrada Therapeutics (TRDA) Net Equity Issued and Repurchased (2021 - 2024) Analysis & Trends
Entrada Therapeutics' Net Equity Issued and Repurchased history runs 3 years deep, the most recent figure standing at -$392000.0 for Q3 2024.
- On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to -$392000.0 in Q3 2024; TTM through Dec 2025 was -$392000.0, a 100.39% decrease from a year earlier, with the FY2024 full-year figure at $99.6 million, up 413.26% from the prior year.
- Net Equity Issued and Repurchased declined to -$392000.0 in Q3 2024 per TRDA's latest filing, from $100.0 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $116.2 million in Q1 2021 and bottomed at -$417000.0 in Q2 2021.
- The 3-year median for Net Equity Issued and Repurchased is $19.4 million (2023), against an average of $47.0 million.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 141.90 Mn |
| 10 | Entrada Therapeutics | 253.11 Mn | 253.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -392,000.00 |
| Sep 30, 2024 | -392,000.00 |
| Jun 30, 2024 | 100.00 Mn |
| Jun 30, 2024 | 100.00 Mn |
| Mar 31, 2023 | 19.41 Mn |
| Mar 31, 2023 | 19.41 Mn |
| Jun 30, 2021 | -417,000.00 |
| Jun 30, 2021 | -417,000.00 |
| Mar 31, 2021 | 116.25 Mn |
| Mar 31, 2021 | 116.25 Mn |